PDS Biotechnology

Q2 FY2026 EarningsQ2 FY2026 missed consensus across bottom-line metrics, with a net loss of $9.8M compared to the $7.3M expected. EPS GAAP was -$0.18, significantly wider than the -$0.13 consensus, driven by a non-cash charge related to debt retirement. However, total operating expenses were lower than expected at $6.5B as the company strategically pivoted to prioritize PDS0301, resulting in a 14.8% YoY reduction in total OpEx.